��Get a skin-cancer check and an appointment with a gynecologist.
��Renew and fill the family's prescriptions.
��Schedule a blood draw for her husband and youngest daughter.
STORY: Is high-deductible health plan right for you?
STUDY: Employees often pick lower-cost plans
Edson sprang to action because her husband's employer drastically changed its health-insurance plan for 2014.
Citing the nation's new health-care law, the company switched to a high-deductible plan that won't pay for medical care until the family spends $4,000 out of pocket.So, like many others, Edson is cramming in all of the health care she can to take advantage of her more generous plan that ends Dec. 31.
Top Freight Companies To Buy For 2015: Cannabis Science Inc (CBIS)
Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).
The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.
Advisors' Opinion:- [By John Udovich]
Small cap marijuana stocks Medical Marijuana Inc (OTCMKTS: MJNA), Cannabis Science Inc (OTCMKTS: CBIS), Medbox Inc (OTCMKTS: MDBX), Growlife Inc (OTCBB: PHOT) and HEMP, Inc (OTCMKTS: HEMP) were all surging by double digits yesterday thanks in part to legal sales of pot beginning in Colorado.
Top 10 Medical Stocks To Invest In 2014: Analogic Corp (ALOG)
Analogic Corporation (Analogic), incorporated in November 27, 1967, is a technology company that designs and manufactures advanced medical imaging and security systems and subsystems sold to Original Equipment Manufacturers (OEMs) and end users primarily in the healthcare and airport security markets. Analogic operate primarily three segments: Medical Imaging, Ultrasound, and Security Technology. Medical Imaging, which primarily includes systems and subsystems for computed tomography (CT) and magnetic resonance imaging (MRI) medical imaging equipment, Selenium-based detectors for screening and diagnostic applications in mammography. Ultrasound, which designs, manufactures, and distributes ultrasound systems and transducers primarily in the urology, surgery, robotic assisted surgery, anesthesia, and general imaging markets. Security Technology, which includes advanced threat detecting CT systems. In March 2013, it completed the acquisition of Ultrasonix Medical Corporation. In September 2013, the Company announced that it has acquired the remaining ownership stake in PocketSonics, Inc.
Medical Imaging
During the fiscal year ended July 31, 2012 (fiscal 2012), the Company�� medical imaging segment, which accounted for approximately 59% of its net revenue, which consists primarily of electronic systems and subsystems for medical imaging, sold globally to OEM producers of CT, MRI, and digital mammography systems. Products under this consist of: X-Ray Detectors, which converts the x-ray energy in a CT machine to useful analog signals for processing in the DAS.
DAS, which are used to process the signals created by the detectors and feed them as a digital stream to a reconstruction computer to create high resolution images. The DAS is designed with many multi-channel circuit boards that process the analog signals from the detectors and convert them into digital signals through an array of analog to digital.
converters. DMS, which the brains of the CT sys! tem and consists of both the detector array and the DAS in one package. This system provides its OEM customers a level of integration that allows for lower cost and faster time to market. Integrated Gantries, which is a component of the CT system (detectors, DAS, x-ray tube and power supplies), are mounted on a rotating ring assembly called a gantry. It provides integrated gantries to its OEM customers as another level of integration.
For OEM producers of MRI equipment, it also supplies two key components: gradient amplifiers and radio frequency, or RF, amplifiers. It has developed a range of amplifier solutions for its customers ranging from low-magnetic-field systems (< 0.3 Tesla) to ultra high-field systems (> 7.0 Tesla) used in academic research hospitals.
Gradient Amplifier, which is a power systems used to drive a set of coils located inside the MRI system and around the patient. The coils energize the atomic structure of patients��anatomy in order to develop tissue and structure images. Gradient amplifiers must be specifically designed for different MRI field strengths ranging from 0.3 Tesla to >7.0 Tesla. RF Amplifiers, which is a power systems used to control another set of the coils within the MRI system that are used to read-back the signals from the anatomy generated by the gradient coils. These signals are then processed in a reconstruction computer to create images. The RF amplifiers must have a high signal-to-noise ratio to produce the cleanest images.
The Company�� digital mammography products consist primarily of digital mammography selenium-based x-ray detector plates, sold directly to OEM customers for screening and diagnostic applications in mammography. These x-ray detector plates are used by OEMs in mammography systems to convert x-ray signals into high resolution two-dimensional (2-D) and three-dimensional (3-D) images of breast tissue to aid in the detection of breast cancer. Its detector plates for mammography applications are sold to! medical ! OEMs for use in products worldwide. Its mammography product portfolio consists of: LMAM, which is its large area detector plate, based on selenium technology, is used primarily for European markets and was recently introduced in the United States market. This detector plate is also compatible with systems that can perform tomosynthesis, which creates 3-D images through a series of exposures to more accurately detect lesions in the breast. SMAM, which is its small area detector plate uses the same selenium-based technology as the LMAM detector and is manufactured primarily for the Asian markets. Within its medical imaging segment, it also designs and manufactures precision motion control systems, which it supplies to OEM customers for use in computer-controlled automation systems primarily in the semiconductor and medical markets.
Ultrasound
The Company�� ultrasound segment designs and manufactures procedure-driven ultrasound systems and transducers, principally under the B-K Medical brand. These products are primarily for end-user markets in urology and surgery and accounted for approximately 29% of its net revenue in fiscal year 2012. Its ultrasound systems use acoustic waves to generate real-time images of the body�� internal anatomy that are used for interventional and medical diagnostic procedures. These ultrasound systems are also used for guiding robotic assisted surgical procedures and for guiding prostate cancer treatment employing a procedure called brachytherapy. It also manufactures and sells advanced ultrasound probes and transducers to medical OEMs.
Security Technology
Utilizing the Company�� CT technology, its Security Technology segment designs and manufactures airport security systems and subsystems primarily for checked bag applications and accounted for approximately 12% of its net revenue in fiscal year 2012. These systems generate 3-D images of objects contained within baggage and provide threat analysis of materials conta! ined with! in the bags. The Company sells the checked baggage systems through L-3 Communications Corporation (L-3): eXaminer XLB (High Speed), eXaminer 3DX (Medium Speed) and eXaminer SX (Reduced Size).
The Company competes with General Electric Corporation (GE) and Koninklijke Philips Electronics N.V. (Philips), Hitachi Medical Corporation, Fujifilm, Morpho Detection and Science Applications International Corp. (SAIC).
Advisors' Opinion:- [By John Udovich]
Small cap security stocks Analogic Corporation (NASDAQ: ALOG), OSI Systems, Inc (NASDAQ: OSIS) and View Systems Inc (OTCBB: VSYM) all aid Big Brother to keep us safe with security inspection systems intended for airports and other public�places rather than equipment to just spy on us. Moreover, the security inspection systems market is global and massive as its not just about detecting potential hijackers at airports as such systems can be used to fight or prevent crime. With that thought in mind, here is a look at three small cap security inspection system stocks:
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Analogic (NASDAQ: ALOG) were down 16.00 percent to $80.11 after the company reported downbeat Q2 earnings. CJS Securities downgraded the stock from Market Outperform to Market Perform and cut the price target from $97.00 to $90.00.
Top 10 Medical Stocks To Invest In 2014: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.
The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.
CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.
Advisors' Opinion:- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
- [By John Kell]
Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.
Top 10 Medical Stocks To Invest In 2014: Curis Inc.(CRIS)
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is base d in Lexington, Massachusetts.
Advisors' Opinion:- [By Monica Gerson]
Curis (NASDAQ: CRIS) dipped 18.97% to $3.16 in the pre-market session after the company reported Q3 financial results and provided CUDC-427 development update.
Top 10 Medical Stocks To Invest In 2014: Regulus Therapeutics Inc (RGLS)
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012, the Company�� operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs.
The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases. The Company intends to focus its resources on product opportunities in therapeutic areas where development and commercialization activities are appropriate for its size and financial resources, which the Company anticipates will include niche indications and orphan diseases.
The Company competes with Groove Biopharma, Inc., miRagen Therapeutics, Inc., Mirna Therapeutics, Inc., and Santaris Pharma A/S.
Advisors' Opinion:- [By Sean Williams]
Regulus Therapeutics (NASDAQ: RGLS )
Since presenting at the Deutsche Bank Healthcare Conference two weeks ago, shares of Regulus Therapeutics have been absolutely on fire. A mixture of ASCO and IPO fever have revived the love for newer issues, and having big name pharmaceutical companies gobbling up a majority of its IPO'd shares certainly helps its cause. - [By Sean Williams]
A blast to the past
It's occasionally very difficult to value biotech stocks, because of the wide range of outcomes possible given their pipelines. Other times, as in the case with Regulus Pharmaceuticals (NASDAQ: RGLS ) , I bang my head against a table and wonder what the heck investors are thinking. - [By Brian Orelli]
Partners like this investment idea
When Regulus Therapeutics (NASDAQ: RGLS ) went public last year, investors weren't the only ones buying the share offering; Regulus' partners and founders clearly thought it was a good investment idea, because they bought more shares. Lots of them. AstraZeneca, Biogen Idec, Sanofi, GlaxoSmithKline�and Isis combined to purchase more than 70% of the shares that raised nearly $81 million for the biotech.
Top 10 Medical Stocks To Invest In 2014: Alpha Pro Tech Ltd (APT)
ALPHA PRO TECH, LTD. (Alpha Pro Tech), incorporated on June 15, 1994, is in the business of protecting people, products and environments. The Company also manufactures a line of building supply construction weatherization products through its wholly-owned subsidiary, Alpha ProTech Engineered Products, Inc. Its products are sold under the Alpha Pro Tech brand name, as well as under private label. The Company's products are grouped into three business segments: the Building Supply segment, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, the Disposable Protective Apparel segment, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products and the Infection Control segment, which consists of face masks and eye shields.
Building Supply
The Building Supply segment consists of a line of construction supply weatherization products, namely housewrap and synthetic roof underlayment. This line of products is a natural extension of the Company's core capabilities: creating products designed to protect people and environments. The housewrap, under the trademark REX, offers a weather resistant barrier and, to the homeowner, years of lower energy consumption. REX Wrap and REX Wrap Plus are woven and coated polypropylene micro perforated weather resistant barriers, and REX Wrap Fortis is an engineered composite made up of a woven fabric, a monolithic breather film and a non-woven sheet, offering a non-perforated membrane.
Disposable Protective Apparel
The Disposable Protective Apparel segment includes many different styles of disposable products, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. The products are manufactured by subcontractors in Asia and, to a much lesser extent, a subcontractor in Mexico. Certain products are made using materials supplied by th! e Company.
Infection Control
The Infection Control segment includes face masks and eye shields. The Company's face masks come in a range of filtration efficiencies and styles. The Company's Positive Facial Locka feature provides a custom fit to the face to prevent blow-by for better protection. The Company's Magic Arch feature holds the mask away from the nose and mouth, creating a comfortable breathing chamber.
Kimberly Clark, 3M Company, Johnson & Johnson, White Knight/Precept, Cardinal Health, Inc., Medline Industries Inc., VWR International, LLC, Kimberly Clark, 3M Company, Kappler USA, DuPont and Allegiance Health Care.
Advisors' Opinion:- [By Cindy Bowser]
Alpha Pro Tech (APT) is a Delaware corporation headquartered in Ontario. APT was our ��ompany of the Month��feature in August 2000 at $1.31 per share.
Top 10 Medical Stocks To Invest In 2014: Insys Therapeutics Inc (INSY)
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company�� pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company�� product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).
Subsys
The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.
Dronabinol Product Family
The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.
Cancer Therapeutics
In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.
The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Advisors' Opinion:- [By David Zeiler]
2. Insys Therapeutics Inc. (Nasdaq: INSY): Insys is a biotech seeking to capitalize on the growing interest in medical marijuana by using a generic form of THC to create drugs to treat cancer pain. INSY had its IPO May 2 with an offer price of $8 a share. The stock rose 19.75% on its first day of trading. But investors really warmed up to Insys later; it currently trades at about $37.54, a 369.25% increase over the offer price.
- [By Traders Reserve]
For example at the end of August, I found a little stock called INSYS Therapeutics (INSY) The company showed up as a top-rated stock using a stock-rating system based on something I call the P/E Gap ��the difference between a stock�� P/E ratio and its expected profit growth rate.
No comments:
Post a Comment